SEC Form 4 · accession 0000899243-19-002512
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lindsey Rolfe
Officer — See Remarks
Period of report
Feb 1, 2019
Accepted (ET)
Feb 4, 2019 · 6:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $25.75 | Feb 1, 2019 | A | 19,996 | A | — | Feb 1, 2029 | Common Stock | 19,996 | 19,996 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 1, 2019 | A | 59,988 | A | — | — | Common Stock | 59,988 | 59,988 | D |
Explanation of responses
- F1The option shall vest as to 25% of the shares on February 1, 2020, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
- F2Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- F3The Restricted Stock Units shall vest as to 25% of the units on February 1, 2020, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance